The state of New York currently has 33 active clinical trials seeking participants for Migraine research studies. These trials are conducted in various cities, including New York, Rochester, Bronx and Buffalo.
A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
Recruiting
The primary objective of the study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment in the pivotal study). Secondary objectives are to evaluate the efficacy of subcutaneous fremanezumab in pediatric participants with migraine and to evaluate the immunogenicity of fremanezumab and the impact of ADAs on clinical outcomes in pediatric participants exposed... Read More
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
02/22/2024
Locations: Teva Investigational Site 14276, Amherst, New York
Conditions: Migraine
GORE® CARDIOFORM Septal Occluder Migraine Clinical Study
Recruiting
Multi-center, prospective, randomized, placebo- and sham-controlled study to evaluate the GORE® CARDIOFORM Septal Occluder for migraine headache relief
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
02/22/2024
Locations: University at Buffalo, Buffalo, New York +2 locations
Conditions: Migraine, Patent Foramen Ovale, PFO - Patent Foramen Ovale
A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Patients 6 to 17 Years of Age
Recruiting
The primary objective of the study is to evaluate the effectiveness of fremanezumab as compared to placebo for the preventive treatment of chronic migraine (CM). Secondary objectives are to further demonstrate the efficacy of Fremanezumab as compared to placebo for the preventive treatment of CM, to evaluate the safety and tolerability of Fremanezumab in the preventive treatment of CM and to evaluate the immunogenicity of Fremanezumab and the impact of antidrug antibodies (ADAs) on clinical out... Read More
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
02/20/2024
Locations: Teva Investigational Site 14276, Amherst, New York
Conditions: Migraine
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Recruiting
A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. A number of treatments are available for adults with migraine but there are limited approved treatments available for pediatric participants. The main goal of the study is to evaluate the safety and efficacy (how well treatment works) of a low-dose and high-dose of atogepant in pediatric par... Read More
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
02/20/2024
Locations: Dent Neurosciences Research Center, Inc. /ID# 248534, Amherst, New York
Conditions: Episodic Migraine
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Recruiting
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
02/16/2024
Locations: Dent Neurosciences Research Center, Amherst, New York +12 locations
Conditions: Pediatric Migraine
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Recruiting
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of moderate or severe migraine in children and adolescents (≥ 6 to < 18 years of age).
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
02/16/2024
Locations: Dent Neurosciences Research Center, Amherst, New York +8 locations
Conditions: Acute Treatment of Migraine
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
Recruiting
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to <18 years with episodic migraine.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
02/16/2024
Locations: Dent Neurosciences Research Center, Inc., Amherst, New York +1 locations
Conditions: Migraine
Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
Recruiting
The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatment for episodic migraine.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2024
Locations: Dent Neurosciences Research Center, Inc., Amherst, New York +2 locations
Conditions: Migraine
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
Recruiting
This study is being conducted to evaluate the efficacy and tolerability of rimegepant in a population of adults that are unsuitable for triptan medications due to a previous intolerance, lack of efficacy, or contraindication (including a history of clinically-relevant cardiovascular disease).
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2024
Locations: Montefiore Medical Center, Bronx, New York +2 locations
Conditions: Migraine
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
Recruiting
This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: Montefiore Medical Center, Bronx, New York +1 locations
Conditions: Migraine
A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
Recruiting
The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/11/2024
Locations: Dent Neurosciences Research Center, Inc., Amherst, New York +6 locations
Conditions: Migraine
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
Recruiting
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with chronic migraine. The study hypothesis is that in pediatric participants with chronic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
02/07/2024
Locations: Dent Neurosciences Research Center, Amherst, New York +2 locations
Conditions: Migraine